Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Zimmer

Showing results (361-370 of 384) with videos related to

Pageof 39
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 15, 2023
Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathologyBruna Bellaver, Albert Puig-Pijoan, João Pedro Ferrari-Souza, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2022
The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [<sup>18</sup>F]MK6240 Tau PET in Target RegionsCécile Tissot, Stijn Servaes, Firoza Z Lussier, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 9, 2025
Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's diseaseBruna Bellaver, Guilherme Povala, Pamela C L Ferreira, et al.
Molecular Psychiatry|August 10, 2022
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer's diseaseJoão Pedro Ferrari-Souza, Pâmela C L Ferreira, Bruna Bellaver, et al.
Nature Medicine|May 29, 2023
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's diseaseBruna Bellaver, Guilherme Povala, Pamela C L Ferreira, et al.
Brain : a Journal of Neurology|January 29, 2025
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrumJaime Fernández Arias, Wagner S Brum, Gemma Salvadó, et al.
The Journal of Prevention of Alzheimer'S Disease|June 5, 2025
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's diseaseSarah Abbas, Pamela C L Ferreira, Bruna Bellaver, et al.
JAMA Neurology|December 12, 2022
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission TomographyJoseph Therriault, Marie Vermeiren, Stijn Servaes, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Clinical ManifestationsJoão Pedro Uglione Da Ros, Lucas Uglione Da Ros, Andrei Bieger, et al.
Nature Neuroscience|November 6, 2025
Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer's diseaseJoão Pedro Ferrari-Souza, Guilherme Povala, Nesrine Rahmouni, et al.
Pageof 39

Showing results (361-370 of 384) with videos related to

Sort By:
Pageof 39
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 15, 2023
Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathologyBruna Bellaver, Albert Puig-Pijoan, João Pedro Ferrari-Souza, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2022
The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [<sup>18</sup>F]MK6240 Tau PET in Target RegionsCécile Tissot, Stijn Servaes, Firoza Z Lussier, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 9, 2025
Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's diseaseBruna Bellaver, Guilherme Povala, Pamela C L Ferreira, et al.
Molecular Psychiatry|August 10, 2022
Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer's diseaseJoão Pedro Ferrari-Souza, Pâmela C L Ferreira, Bruna Bellaver, et al.
Nature Medicine|May 29, 2023
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's diseaseBruna Bellaver, Guilherme Povala, Pamela C L Ferreira, et al.
Brain : a Journal of Neurology|January 29, 2025
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrumJaime Fernández Arias, Wagner S Brum, Gemma Salvadó, et al.
The Journal of Prevention of Alzheimer'S Disease|June 5, 2025
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's diseaseSarah Abbas, Pamela C L Ferreira, Bruna Bellaver, et al.
JAMA Neurology|December 12, 2022
Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission TomographyJoseph Therriault, Marie Vermeiren, Stijn Servaes, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Clinical ManifestationsJoão Pedro Uglione Da Ros, Lucas Uglione Da Ros, Andrei Bieger, et al.
Nature Neuroscience|November 6, 2025
Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer's diseaseJoão Pedro Ferrari-Souza, Guilherme Povala, Nesrine Rahmouni, et al.
Pageof 39